Enda Byrne

Senior Research Fellow

University of Queensland
Country flagAustralia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Twin studies reveal high genetic overlap between anxiety disorders and depression, contributing to the internalising spectrum. Some genetic specificity for fear-based anxiety disorders (fear), distinct from general anxiety and depression (distress), has also emerged. Limited datasets with detailed phenotyping across anxiety disorders have restricted most genome-wide association studies (GWAS) to “any anxiety diagnosis”. Additional genome-wide evidence to discern genetic differences between fear and distress is required. We conducted GWAS meta-analyses of fear (panic, agoraphobia, specific phobia, social anxiety disorder) and generalised anxiety disorder (GAD), measured using brief single-item and detailed symptom-based diagnoses from three datasets. We explored two control group criteria: phenotype-specific (fear/GAD) or broader anxiety/depression screening. We identified one SNP-based independent locus and three gene-level genome-wide significant (GWS) associations with fear (up to 35,523 N cases ; 157,447 N controls ). Four GWS SNP-based loci and three gene-level loci were associated with GAD (up to 60,879 N cases ; 117,064 N controls ). The genetic correlation between fear and GAD was significantly different from unity only when excluding a depression-enriched dataset and using phenotype-specific control screening (r g = 0.87; P = 9.32 × 10 −3 ). Most complex traits had statistically similar genetic correlations with fear and GAD, including depression. Exceptions included general cognitive ability, educational attainment, and coronary artery disease, showing statistically stronger genetic correlations with fear than GAD, while bipolar disorder type I, anorexia nervosa, and neuroticism displayed the opposite pattern. Our findings partially support a distress-fear genetic distinction, but show stronger evidence for an overarching genetic liability to internalising psychopathology driving comorbidity across anxiety disorders and depression.

Year:

2026

There are striking sex differences in the prevalence and symptomology of Major Depressive Disorder. Here, we conduct the largest sex-stratified genome wide association and genotype-by-sex interaction meta-analyses of Major Depressive Disorder to date (Females: 130,471 cases, 159,521 controls. Males: 64,805 cases, 132,185 controls). We identify 16 and eight independent genome-wide significant variants in females and males, respectively, including one novel variant on the X chromosome. Major Depressive Disorder in females and males shows substantial genetic overlap with a large proportion of variants displaying similar effect sizes across sexes. However, we also provide evidence for a higher burden of genetic risk in females which could be due to female-specific variants. Additionally, sex-specific pleiotropic effects may contribute to the higher prevalence of metabolic symptoms in females with Major Depressive Disorder. These findings underscore the importance of considering sex-specific genetic architectures in the study of health conditions, including Major Depressive Disorder, paving the way for more targeted treatment strategies.

Year:

2025

Background Increasing daylight exposure might be a simple way to improve mental health. However, little is known about daylight-symptom associations in depressive disorders. Methods In a subset of the Australian Genetics of Depression Study ( N = 13,480; 75% female), we explored associations between self-reported number of hours spent in daylight on a typical workday and free day and seven symptom dimensions: depressive (overall, somatic, psychological); hypo-manic-like; psychotic-like; insomnia; and daytime sleepiness. Polygenic scores for major depressive disorder (MDD); bipolar disorder (BD); and schizophrenia (SCZ) were calculated. Models were adjusted for age, sex, shift work status, employment status, season, and educational attainment. Exploratory analyses examined age-stratified associations (18–24 years; 25–34 years; 35–64 years; 65 and older). Bonferroni-corrected associations ( p < 0.004) are discussed. Results Adults with depression reported spending a median of one hour in daylight on workdays and three hours on free days. More daylight exposure on workdays and free days was associated with lower depressive (overall, psychological, somatic) and insomnia symptoms ( p ’s<0.001), but higher hypo-manic-like symptoms ( p ’s<0.002). Genetic loading for MDD and SCZ were associated with less daylight exposure in unadjusted correlational analyses (effect sizes were not meaningful). Exploratory analyses revealed age-related heterogeneity. Among 18–24-year-olds, no symptom dimensions were associated with daylight. By contrast, for the older age groups, there was a pattern of more daylight exposure and lower insomnia symptoms ( p < 0.003) (except for 25–34-year-olds on free days, p = 0.019); and lower depressive symptoms with more daylight on free days, and to some extent workdays (depending on the age-group). Conclusions Exploration of the causal status of daylight in depression is warranted.

Year:

2025

Year:

2025

Importance Antidepressant treatment remains largely trial-and-error, with approximately one-third of patients with major depressive disorder (MDD) reporting inefficacy of first-line medications. Identifying predictors of treatment acceptability is needed to improve prescribing precision and patient outcomes. Objective To identify phenotypic and genetic signatures associated with antidepressant acceptability and treatment complexity. Design, Setting, and Participants Retrospective cohort study of Australian Genetics of Depression Study participants dispensing ≥1 prescription of the 10 most commonly used antidepressants, based on linked 4.5-year (2013–2017) prescription data. Exposures Treatment complexity was assessed as number of antidepressant classes dispensed. Antidepressant acceptability was defined as sustained single-antidepressant use (≥360 cumulative days). Participants with genotyping data were classified into mutually exclusive groups based on sustained single-medication use. Main Outcomes and Measures Associations with 40 phenotypes and polygenic scores (PGS) for 15 traits. Genome-wide association studies (GWAS) were conducted for SSRI and SSRI/SNRI antidepressant acceptability. Results Of 13,763 participants with ≥1 antidepressant prescription, 9,844 had genotyping data (mean [SD] age 44.5 [15.0] years; 26% male; 89% lifetime MDD). Treatment complexity was significantly associated with 27 of 40 phenotypes (e.g., smoking, recurrent MDD, suicidal ideation, chronic pain, BMI) and higher PGSs for psychiatric traits (MDD, ADHD, bipolar disorder, neuroticism; β = 0.028– 0.045 per PGS SD unit, p = 9.9 × 10 -6 to 2.1 × 10 -10 ). Sixty percent met criteria for an exclusive antidepressant acceptability group. These groups had distinct phenotypic profiles, including associations with BMI, suicidal ideation, and comorbidities. In particular, only SNRI users had higher BMI than SSRI users, but this association was explained by the BMI PGS, indicating genetic rather than treatment-induced differences. GWAS identified novel loci including an immune-related gene LY9 , for which the G allele of rs6427545 was associated with reduced SSRI acceptability (frequency = 0.31; OR = 0.82; p = 2.8 × 10 -8 ) Conclusions and Relevance Antidepressant acceptability and complex treatment patterns correspond to distinct phenotypic and genetic signatures. PGS demonstrate potential for enabling precision psychiatry, and immune-related pathways warrant therapeutic investigation. Key Points Question Can phenotypic and genetic factors help identify individuals likely to show antidepressant-specific acceptability and treatment complexity, improving treatment precision in major depressive disorder (MDD)? Findings In this cohort study of 13,763 individuals with antidepressant prescriptions, treatment complexity was associated with 27 self-reported phenotypic traits and higher polygenic scores (PGS) for psychiatric conditions. Among 9,844 genotyped participants, 60% met criteria for single-antidepressant acceptability, with distinct phenotypic and genetic profiles. Notably, higher BMI among sustained SNRI users was explained by genetic predisposition. A genome-wide association study identified novel loci, including an immune-related gene ( LY9 ), associated with reduced SSRI acceptability. Meaning Phenotypic and genetic factors, including PGS, are associated with both antidepressant acceptability and treatment complexity. These findings support the use of such markers to guide treatment selection and identify patients at risk for more complex courses, informing precision psychiatry and early intervention in MDD.

Year:

2025

Background Atypical depression is considered a distinct clinical subtype of major depression, yet its predictive validity and clinical utility remain contested. We investigated association between atypical depression and clinical characteristics, genetic profiles, and antidepressant responses. Methods Among 14,897 participants from the Australian Genetics of Depression Study (75% female; mean age 43.7 years), 3,098 (21%) were classified phenotypically as having “atypical depression” based on self-reported weight gain and hypersomnia during their worst depressive episode. Demographics and clinical features were compared. Bonferroni-corrected regression models assessed associations between atypical depression and polygenic scores (PGS) for mental disorders, metabolic-inflammatory-circadian traits, and self-reported antidepressant response and side effects. Results Atypical depression cases had an earlier age of onset, greater illness severity, stronger eveningness and reduced daylight exposure. Atypical depression cases had higher PGS for major depressive disorder (odds ratio [OR]=1.10 [95%CI: 1.06-1.15]), attention-deficit/hyperactivity disorder (OR=1.08 [1.04-1.13]), bipolar disorder (OR= 1.07 [1.02-1.12]), neuroticism (OR=1.07 [1.02-1.12]), BMI (OR=1.35 [1.29-1.42]), Type 2 diabetes (OR=1.22 [1.16-1.28]), C-reactive protein (OR=1.12 [1.07-1.17]), and insulin resistance (OR=1.11 [1.06-1.16]) but lower PGS for HDL cholesterol (OR=0.91 [0.87-0.95]) and chronotype (indicating eveningness; OR=0.94 [0.90-0.98]). Atypical depression was associated with poorer efficacy of selective serotonin reuptake inhibitors (OR=0.88 [0.81-0.96]) and serotonin-norepinephrine reuptake inhibitors (OR=0.85 [0.77-0.94]), along with more side effects, particularly weight gain (OR=2.89 [2.66-3.15]). Conclusions This large genetically-informative study supports the neurobiological and clinical validity of atypical depression, demonstrating distinct clinical and genetic risk profiles alongside differential antidepressant responses. These support utilizing the atypical subtype to guide treatment selection and physical health management.

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Collaborators (64)

Mirim Shin

University of Sydney

AUSTRALIA
View details

Harold Snieder

Scientific Staff

University Medical Center Groningen

NETHERLANDS
View details

Naomi Wray

University of Queensland

AUSTRALIA
View details

Sue Cotton

Professor

MONASH UNIVERSITY

AUSTRALIA
View details

Sang hyuck Lee

King’s College London

UNITED KINGDOM
View details

Monika McAtarsney-Kovacs

Anglia Ruskin University

UNITED KINGDOM
View details

Ian Jones

Director National Centre for Mental Health, Professor of Psychiatry

Cardiff University

UNITED KINGDOM
View details

Alex Kwong

Academic , Senior Research Associate

University of Bristol

UNITED KINGDOM
View details

Gerome Breen

Professor of Psychiatric Genetics

King’s College London

UNITED KINGDOM
View details

Nathan Skene

Associate Professor and UK DRI Group Leader

Imperial College London

UNITED KINGDOM
View details

Clara Albiñana

Aarhus University

DENMARK
View details

Nicholas Timpson

Academic , Professor of Genetic Epidemiology

University of Bristol

UNITED KINGDOM
View details

Andrew McIntosh

Professor of Biological Psychiatry

University of Edinburgh

UNITED KINGDOM
View details

Alexandra Havdahl

Prof

Norwegian Institute of Public Health

NORWAY
View details

Chloe Yap

Clinical Researcher

University of Oxford

UNITED KINGDOM
View details

Matthew Hotopf

South London and Maudsley NHS Foundation Trust

UNITED KINGDOM
View details

Cherie Armour

The Queen's University Belfast

UNITED KINGDOM
View details

Serena Sanna

Scientific Staff

University Medical Center Groningen

NETHERLANDS
View details

Colette Hirsch

Professor of Cognitive Clinical Psychology

King’s College London

UNITED KINGDOM
View details

Maxime Taquet

Associate Professor

University of Oxford

UNITED KINGDOM
View details

Albertine J. Oldehinkel

Scientific Staff, Professor

University Medical Center Groningen

NETHERLANDS
View details

F. Huider

University of Amsterdam

NETHERLANDS
View details

Daniel Adkins

Full Professor

University of Utah

UNITED STATES
View details

Brittany Mitchell

Senior Research Fellow

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Iiris Hovatta

University of Helsinki

FINLAND
View details

Alan Murphy

Imperial College London

UNITED KINGDOM
View details

Lianne Schmaal

Professor

University of Melbourne

AUSTRALIA
View details

Juergen Hoyer

Professor

-

GERMANY
View details

Catharina A. Hartman

-

NETHERLANDS
View details

Evangelos Vassos

Clinical Reader

King’s College London

UNITED KINGDOM
View details

Anna Elisabeth Fürtjes

Research Associate in Statistical Genetics

University of Edinburgh

UNITED KINGDOM
View details

James Walters

Director and Clinical Professor

Cardiff University

UNITED KINGDOM
View details

Sarah Medland

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Donald M. Lyall

-

UNITED KINGDOM
View details

David Whiteman

Deputy Director

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Nathalie Kingston

Research Professor

University of Cambridge

UNITED KINGDOM
View details

Michelle Lupton

Team Head

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Shin Ho Park

University of Sydney

AUSTRALIA
View details

Jan Richter

University of Hildesheim

GERMANY
View details

Michela Noseda

Imperial College London

UNITED KINGDOM
View details

Geneviève Morneau-Vaillancourt

Professeure adjointe

Université de Sherbrooke

CANADA
View details

Nicholas Martin

Senior Scientist and Senior Principal Research Fellow

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Mary-Ellen Lynall

Clinical Lecturer

University of Cambridge

UNITED KINGDOM
View details

Christel Middeldorp

Professor

-

NETHERLANDS
View details

Andrea Cipriani

Director

University of Oxford

UNITED KINGDOM
View details

Daniel J Smith

Chair of Psychiatry

University of Edinburgh

UNITED KINGDOM
View details

Jacob J. Crouse

University of Sydney

AUSTRALIA
View details

Elham Assary

King’s College London

UNITED KINGDOM
View details

Cisca Wijmenga

Lodewijk Sandkuijl distinguished university professor of human genetics

University Medical Center Groningen

NETHERLANDS
View details

Miguel Garcia-Argibay

University of Southampton

UNITED KINGDOM
View details

Ian B. Hickie

Co-Director Health and Policy

University of Sydney

AUSTRALIA
View details

Christopher Hübel

VIP, Researcher

Aarhus University

DENMARK
View details

Catherine Olsen

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Jonathan Coleman

Senior Lecturer in Statistical Genetics

King’s College London

UNITED KINGDOM
View details

Teemu Palviainen

University of Helsinki

FINLAND
View details

Georg W. Alpers

University of Mannheim

GERMANY
View details

Jaakko Kaprio

Research Director

University of Helsinki

FINLAND
View details

Thalia Eley

Professor of Developmental Behavioural Genetics

King’s College London

UNITED KINGDOM
View details

Roland Zahn

King’s College London

UNITED KINGDOM
View details

Peter Koval

Professor

University of Melbourne

AUSTRALIA
View details

Johan Zvrskovec

Karolinska Institutet

SWEDEN
View details

Simon Rice

Associate Professor

University of Melbourne

AUSTRALIA
View details

Saakshi Kakar

King's College London

UNITED KINGDOM
View details

Molly Davies

King’s College London

UNITED KINGDOM
View details